Therefore, this immunotherapy approach that may increase the memory T-cell subset holds promise as exemplified in the GOLFIG-2 phase II clinical trial where increased numbers of CD8+ CCR7+ cells in the TME were associated with improved overall and disease-free survival in CRC patients [16, 18, 49–51]. This evidence concerns the gene CD8A and colorectal carcinoma.